Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.91
NYSE:BAX's Cash to Debt is ranked lower than
56% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. NYSE:BAX: 0.91 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:BAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.31 Max: 1.13
Current: 0.91
0.09
1.13
Equity to Asset 0.55
NYSE:BAX's Equity to Asset is ranked lower than
55% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NYSE:BAX: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:BAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.34 Max: 0.55
Current: 0.55
0.22
0.55
Interest Coverage 5.85
NYSE:BAX's Interest Coverage is ranked lower than
82% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.78 vs. NYSE:BAX: 5.85 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.86 Max: 32.02
Current: 5.85
3.08
32.02
F-Score: 5
Z-Score: 5.36
M-Score: -2.51
WACC vs ROIC
6.11%
6.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 6.13
NYSE:BAX's Operating margin (%) is ranked higher than
56% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.66 vs. NYSE:BAX: 6.13 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:BAX' s Operating margin (%) Range Over the Past 10 Years
Min: 4.5  Med: 18.5 Max: 22.9
Current: 6.13
4.5
22.9
Net-margin (%) 48.68
NYSE:BAX's Net-margin (%) is ranked higher than
99% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.06 vs. NYSE:BAX: 48.68 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:BAX' s Net-margin (%) Range Over the Past 10 Years
Min: 9.71  Med: 16.16 Max: 48.68
Current: 48.68
9.71
48.68
ROE (%) 57.46
NYSE:BAX's ROE (%) is ranked higher than
98% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. NYSE:BAX: 57.46 )
Ranked among companies with meaningful ROE (%) only.
NYSE:BAX' s ROE (%) Range Over the Past 10 Years
Min: 11.41  Med: 28.27 Max: 57.46
Current: 57.46
11.41
57.46
ROA (%) 27.29
NYSE:BAX's ROA (%) is ranked higher than
99% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. NYSE:BAX: 27.29 )
Ranked among companies with meaningful ROA (%) only.
NYSE:BAX' s ROA (%) Range Over the Past 10 Years
Min: 4.11  Med: 10.79 Max: 27.29
Current: 27.29
4.11
27.29
ROC (Joel Greenblatt) (%) 83.11
NYSE:BAX's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. NYSE:BAX: 83.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:BAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 5.65  Med: 37.11 Max: 83.11
Current: 83.11
5.65
83.11
Revenue Growth (3Y)(%) -10.20
NYSE:BAX's Revenue Growth (3Y)(%) is ranked lower than
80% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. NYSE:BAX: -10.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:BAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.2  Med: 6.7 Max: 17.3
Current: -10.2
-10.2
17.3
EBITDA Growth (3Y)(%) -28.30
NYSE:BAX's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. NYSE:BAX: -28.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:BAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: 6.6 Max: 33.1
Current: -28.3
-28.3
33.1
EPS Growth (3Y)(%) -44.00
NYSE:BAX's EPS Growth (3Y)(%) is ranked lower than
94% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. NYSE:BAX: -44.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:BAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44  Med: 7.1 Max: 61.5
Current: -44
-44
61.5
GuruFocus has detected 8 Warning Signs with Baxter International Inc $NYSE:BAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:BAX's 10-Y Financials

Financials (Next Earnings Date: 2017-02-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BAX Guru Trades in Q1 2016

Joel Greenblatt 1,695,068 sh (New)
David Einhorn 1,198,663 sh (+138.07%)
Keeley Asset Management Corp 61,500 sh (+21.66%)
Vanguard Health Care Fund 11,176,980 sh (+16.94%)
Jim Simons 517,032 sh (+5.06%)
Murray Stahl 14,122 sh (+0.71%)
Daniel Loeb 53,850,000 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Tom Gayner 22,000 sh (unchged)
John Rogers Sold Out
Jana Partners Sold Out
Lee Ainslie Sold Out
Jeff Auxier Sold Out
Louis Moore Bacon Sold Out
Tweedy Browne 2,492,683 sh (-0.12%)
Charles Brandes 310,615 sh (-1.51%)
Mario Gabelli 153,750 sh (-2.01%)
John Buckingham 81,062 sh (-5.58%)
Manning & Napier Advisors, Inc 149,096 sh (-6.94%)
George Soros 448,200 sh (-9.45%)
Mairs and Power 2,035,912 sh (-9.63%)
Richard Pzena 4,084,406 sh (-13.78%)
Paul Tudor Jones 64,681 sh (-19.04%)
Jeremy Grantham 32,592 sh (-37.62%)
Steven Cohen 51,000 sh (-94.26%)
First Eagle Investment 1,100 sh (-99.86%)
» More
Q2 2016

BAX Guru Trades in Q2 2016

Lee Ainslie 73,700 sh (New)
Leucadia National 700,000 sh (New)
John Hussman 175,000 sh (New)
First Eagle Investment 2,129,733 sh (+193512.09%)
Jim Simons 583,200 sh (+12.80%)
Jeremy Grantham 36,465 sh (+11.88%)
Tom Gayner 22,000 sh (unchged)
Murray Stahl 14,122 sh (unchged)
David Einhorn Sold Out
John Buckingham Sold Out
Manning & Napier Advisors, Inc Sold Out
Tweedy Browne Global Value 1,055,212 sh (-3.62%)
Daniel Loeb 51,901,767 sh (-3.62%)
Tweedy Browne 2,393,665 sh (-3.97%)
Mairs and Power 1,948,504 sh (-4.29%)
Keeley Asset Management Corp 58,610 sh (-4.70%)
Mario Gabelli 125,100 sh (-18.63%)
Richard Pzena 3,115,865 sh (-23.71%)
George Soros 284,327 sh (-36.56%)
Vanguard Health Care Fund 7,053,480 sh (-36.89%)
Joel Greenblatt 849,128 sh (-49.91%)
Paul Tudor Jones 27,459 sh (-57.55%)
Charles Brandes 75,584 sh (-75.67%)
Steven Cohen 3,600 sh (-92.94%)
» More
Q3 2016

BAX Guru Trades in Q3 2016

Steven Cohen 227,300 sh (+6213.89%)
First Eagle Investment 2,635,577 sh (+23.75%)
Paul Tudor Jones 33,174 sh (+20.81%)
John Hussman 200,000 sh (+14.29%)
Daniel Loeb 51,901,767 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Jeremy Grantham Sold Out
Leucadia National Sold Out
Charles Brandes Sold Out
Mario Gabelli 123,500 sh (-1.28%)
Keeley Asset Management Corp 57,410 sh (-2.05%)
Mairs and Power 1,903,688 sh (-2.30%)
Lee Ainslie 67,360 sh (-8.60%)
Tweedy Browne 2,157,391 sh (-9.87%)
George Soros 254,327 sh (-10.55%)
Joel Greenblatt 638,063 sh (-24.86%)
Vanguard Health Care Fund 4,902,940 sh (-30.49%)
Richard Pzena 1,061,577 sh (-65.93%)
Jim Simons 158,000 sh (-72.91%)
» More
Q4 2016

BAX Guru Trades in Q4 2016

Tweedy Browne Global Value 1,055,212 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ILMN, OTCPK:ESLOY, NYSE:BCR, OTCPK:CLPBY, OTCPK:TRUMY, NAS:XRAY, OTCPK:OCPNF, NYSE:WAT, NAS:HOLX, NYSE:MTD, NYSE:BDX, NYSE:RMD, NYSE:COO, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:HRC, OTCPK:GNGBF, NYSE:CMD, OTCPK:ANSLY » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.

Baxter International Inc was incorporated in Delaware in 1931. The Company is a healthcare company. It is engaged in the development, manufacture and sale of products that save and sustain the lives of people with immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely, Hospital Products and Renal. The Hospital Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. The Renal business also offers a portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis (PD), in-center hemodialysis (HD), home HD (HHD), continuous renal replacement therapy (CRRT) and additional dialysis services. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.

Guru Investment Theses on Baxter International Inc

Bill Nygren Comments on Baxter - Jan 10, 2017

Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value.



From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2016 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Baxter International Inc

Bill Nygren Comments on Baxter Guru stock highlight
Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value. Read more...
Vanguard Health Care Fund Sells Amgen, Baxter The guru's largest 3rd-quarter sales
Following its third-quarter report, Vanguard Health Care Fund (Trades, Portfolio) holds 73 stocks with a total value of $46.245 billion. The following are the sales with the largest impacts on its portfolio. Read more...
Medical Companies Offer Good Value Opportunities A discussion of Peter Lynch, his top-performing strategies and good health care companies
Due to the great financial crisis, most companies were undervalued based on their valuations. Based on backtesting results, the “Peter Lynch Growth with Lower Valuation” test portfolio took positions in Baxter International Inc. (NYSE:BAX) and Abbott Laboratories (NYSE:ABT), two medical companies that reached historically low price-earnings ratios. While these companies presented good value opportunities from 2007-2011, other medical companies provide better opportunities in 2016. Read more...
2 CEOs Make Big Buys of Their Companies’ Stocks Purchases may benefit their respective companies
One of the biggest insider buys of the week occurred yesterday when Flex Pharma Inc. (NASDAQ:FLKS) president and CEO Christoph H. Westphal bought 30,334 shares at an average price of $12.42, a move that may signal a positive outlook for the company. Read more...
Baxter International Officer Invests in Stake CEO purchases 11,691 shares in the company
Jose (Joe) Almeida (Insider Trades), CEO and chairman of the board of Baxter International Inc. (BAX), acquired 11,691 shares of the company on May 23. Read more...
Dan Loeb's Third Point Portfolio Highly Concentrated The top position is in the green and tries to offset the negative performances of the other 2
Daniel Loeb´s Third Point disclosed an equity portfolio valued at some $9.86 billion at the end of the fourth quarter of 2015. The equity portfolio is mainly invested in Health Care (53%), Materials (17%) and Consumer Discretionary (11%) stocks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 5.20
BAX's P/E(ttm) is ranked higher than
97% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.41 vs. BAX: 5.20 )
Ranked among companies with meaningful P/E(ttm) only.
BAX' s P/E(ttm) Range Over the Past 10 Years
Min: 4.93  Med: 9.46 Max: 22.53
Current: 5.2
4.93
22.53
Forward P/E 21.88
BAX's Forward P/E is ranked higher than
59% of the 37 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.27 vs. BAX: 21.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 5.22
BAX's PE(NRI) is ranked higher than
96% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.86 vs. BAX: 5.22 )
Ranked among companies with meaningful PE(NRI) only.
BAX' s PE(NRI) Range Over the Past 10 Years
Min: 4.96  Med: 10.13 Max: 115.67
Current: 5.22
4.96
115.67
Price/Owner Earnings (ttm) 5.85
BAX's Price/Owner Earnings (ttm) is ranked higher than
94% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.39 vs. BAX: 5.85 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BAX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.57  Med: 11.78 Max: 37.62
Current: 5.85
5.57
37.62
P/B 2.90
BAX's P/B is ranked higher than
55% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. BAX: 2.90 )
Ranked among companies with meaningful P/B only.
BAX' s P/B Range Over the Past 10 Years
Min: 2.05  Med: 2.62 Max: 3.34
Current: 2.9
2.05
3.34
P/S 2.53
BAX's P/S is ranked higher than
53% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. BAX: 2.53 )
Ranked among companies with meaningful P/S only.
BAX' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 1.57 Max: 2.66
Current: 2.53
1.06
2.66
PFCF 33.18
BAX's PFCF is ranked lower than
62% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.12 vs. BAX: 33.18 )
Ranked among companies with meaningful PFCF only.
BAX' s PFCF Range Over the Past 10 Years
Min: 6.96  Med: 11.3 Max: 266.13
Current: 33.18
6.96
266.13
POCF 16.61
BAX's POCF is ranked higher than
55% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.81 vs. BAX: 16.61 )
Ranked among companies with meaningful POCF only.
BAX' s POCF Range Over the Past 10 Years
Min: 4.58  Med: 7.24 Max: 20.63
Current: 16.61
4.58
20.63
EV-to-EBIT 5.10
BAX's EV-to-EBIT is ranked higher than
95% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.29 vs. BAX: 5.10 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2940.9  Med: 8.6 Max: 63.8
Current: 5.1
-2940.9
63.8
EV-to-EBITDA 4.37
BAX's EV-to-EBITDA is ranked higher than
94% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.68 vs. BAX: 4.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 6.8 Max: 45.7
Current: 4.37
4.3
45.7
Shiller P/E 10.90
BAX's Shiller P/E is ranked higher than
93% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.08 vs. BAX: 10.90 )
Ranked among companies with meaningful Shiller P/E only.
BAX' s Shiller P/E Range Over the Past 10 Years
Min: 9.67  Med: 12.73 Max: 21.71
Current: 10.9
9.67
21.71
Current Ratio 2.53
BAX's Current Ratio is ranked higher than
53% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.44 vs. BAX: 2.53 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.67 Max: 2.7
Current: 2.53
1.08
2.7
Quick Ratio 1.93
BAX's Quick Ratio is ranked higher than
60% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BAX: 1.93 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.13 Max: 2.02
Current: 1.93
0.74
2.02
Days Inventory 98.38
BAX's Days Inventory is ranked higher than
66% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.20 vs. BAX: 98.38 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 98.38  Med: 138.8 Max: 219.03
Current: 98.38
98.38
219.03
Days Sales Outstanding 62.71
BAX's Days Sales Outstanding is ranked higher than
50% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.71 vs. BAX: 62.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 65.15 Max: 112.88
Current: 62.71
58.53
112.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.10
BAX's Dividend Yield is ranked lower than
60% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.29 vs. BAX: 1.10 )
Ranked among companies with meaningful Dividend Yield only.
BAX' s Dividend Yield Range Over the Past 10 Years
Min: 0.98  Med: 3.86 Max: 5.89
Current: 1.1
0.98
5.89
Dividend Payout 0.06
BAX's Dividend Payout is ranked higher than
98% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.32 vs. BAX: 0.06 )
Ranked among companies with meaningful Dividend Payout only.
BAX' s Dividend Payout Range Over the Past 10 Years
Min: 0.06  Med: 0.35 Max: 3.37
Current: 0.06
0.06
3.37
Dividend Growth (3y) -6.80
BAX's Dividend Growth (3y) is ranked lower than
77% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.90 vs. BAX: -6.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.8  Med: 1.7 Max: 22.5
Current: -6.8
-6.8
22.5
Forward Dividend Yield 1.12
BAX's Forward Dividend Yield is ranked lower than
60% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BAX: 1.12 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.47
BAX's Yield on cost (5-Year) is ranked lower than
58% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. BAX: 1.47 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.31  Med: 5.14 Max: 7.85
Current: 1.47
1.31
7.85
3-Year Average Share Buyback Ratio -0.10
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. BAX: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: -0.9 Max: 3.3
Current: -0.1
-2.1
3.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.26
BAX's Price/Tangible Book is ranked lower than
55% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. BAX: 5.26 )
Ranked among companies with meaningful Price/Tangible Book only.
BAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.43  Med: 5.62 Max: 15.06
Current: 5.26
3.43
15.06
Price/Projected FCF 1.09
BAX's Price/Projected FCF is ranked higher than
86% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. BAX: 1.09 )
Ranked among companies with meaningful Price/Projected FCF only.
BAX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.11 Max: 2.82
Current: 1.09
0.53
2.82
Price/Median PS Value 1.62
BAX's Price/Median PS Value is ranked lower than
77% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.09 vs. BAX: 1.62 )
Ranked among companies with meaningful Price/Median PS Value only.
BAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 0.96 Max: 1.65
Current: 1.62
0.45
1.65
Price/Graham Number 1.11
BAX's Price/Graham Number is ranked higher than
80% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BAX: 1.11 )
Ranked among companies with meaningful Price/Graham Number only.
BAX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 1.85 Max: 7
Current: 1.11
1.09
7
Earnings Yield (Greenblatt) (%) 19.64
BAX's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. BAX: 19.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 11.4 Max: 20.4
Current: 19.64
1.6
20.4
Forward Rate of Return (Yacktman) (%) 0.40
BAX's Forward Rate of Return (Yacktman) (%) is ranked lower than
73% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.15 vs. BAX: 0.40 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.9  Med: 14.4 Max: 28
Current: 0.4
-11.9
28

More Statistics

Revenue (TTM) (Mil) $10,121
EPS (TTM) $ 8.92
Beta0.68
Short Percentage of Float1.71%
52-Week Range $34.06 - 50.16
Shares Outstanding (Mil)543.92

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 10,172 10,515 10,924
EPS ($) 1.83 2.12 2.48
EPS w/o NRI ($) 1.83 2.12 2.48
EPS Growth Rate
(3Y to 5Y Estimate)
18.51%
Dividends Per Share ($) 0.55 0.61 0.61
» More Articles for BAX

Headlines

Articles On GuruFocus.com
Steven Romick Spots Next Area of Interest, Health Care Jan 13 2017 
Bill Nygren Comments on Baxter Jan 10 2017 
10 Stocks Trading Below Their Graham Number Dec 19 2016 
10 Undervalued Stocks for the Defensive Investor Dec 15 2016 
10 Stocks for Using a Benjamin Graham Value Investing Strategy Dec 09 2016 
10 Low PE Stocks for the Defensive Investor Dec 08 2016 
9 Stocks First Eagle Keeps Buying Nov 10 2016 
Vanguard Health Care Fund Sells Amgen, Baxter Nov 02 2016 
Medical Companies Offer Good Value Opportunities Sep 16 2016 
10 Undervalued Stocks for the Defensive Investor Sep 13 2016 

More From Other Websites
Baxter to Present at the 6th Annual Leerink Partners Global Healthcare Conference Jan 19 2017
Baxter’s Renal Therapy Services Significantly Reduced Peritonitis Infections among Home Dialysis... Jan 19 2017
Spectrum Health Recognized for Excellence in Community Service with 2016 Foster G. McGaw Prize Jan 18 2017
Baxter (BAX): Sluggish Macro Environment Mars Prospects Jan 18 2017
Baxter to pay $18 mln over mold at North Carolina plant Jan 12 2017
Baxter Healthcare to pay $18 mln to resolve liability -U.S. Jan 12 2017
Baxter International, Inc. – Value Analysis (NYSE:BAX) : January 11, 2017 Jan 11 2017
Blog Coverage Teleflex's Arrow(R) VPS Rhythm(TM) Device gets FDA Clearance; Launches Laryngeal Mask Jan 11 2017
Bill Nygren's Oakmark Fund Commentary: Fourth Quarter 2016 Jan 10 2017
Baxter International, Inc. breached its 50 day moving average in a Bullish Manner : BAX-US : January... Jan 10 2017
New Data Show U.S. Hospital Readmissions are 54 Percent Higher for Malnourished Patients Jan 09 2017
Baxter International Inc. to Host Fourth Quarter 2016 Financial Results Conference Call for... Jan 06 2017
Baxter International Inc. to Host Fourth Quarter 2016 Financial Results Conference Call for... Jan 06 2017
Is Baxter Poised to Counter Low Cyclophosphamide Sales? Dec 30 2016
Boston Scientific Down on Risks; Innovations Raise Hope Dec 27 2016
Financial Metrics of Baxter’s Acquisition of Claris Injectables Dec 26 2016
How Baxter’s Acquisition of Claris Injectables Could Boost Growth Dec 23 2016
Baxter Advances Portfolio with Acquisition of Claris Injectables Dec 23 2016
What Do Analysts Recommend for Baxter International? Dec 23 2016
Myriad Genetics: United Rheumatology Selects Vectra DA Test Dec 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)